Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | RET | P07949 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29059172 | 1.00 | POLB (0.37) | POLBKDM4EALDH1A1HTR6MAPT | |
| SCHEMBL27926854 | 0.92 | HCAR2 (0.38) | POLBKDM4EALDH1A1MAPTHCAR2 | |
| SCHEMBL27902025 | 0.91 | POLB (0.34) | POLBKDM4EALDH1A1RETLMNA | |
| SCHEMBL9308792 | 0.88 | LMNA (0.43) | ALDH1A1MAPTCYP2D6HCAR2LMNA | |
| SCHEMBL15665769 | 0.87 | POLB (0.35) | POLBKDM4EALDH1A1HTR6HTR2A | |
| SCHEMBL6700611 | 0.84 | POLB (0.39) | POLBKDM4EALDH1A1HTR6MAPT | |
| SCHEMBL30931450 | 0.82 | POLB (0.38) | POLBKDM4EALDH1A1HTR6HTR2A | |
| SCHEMBL89374 | 0.81 | POLB (0.49) | POLBKDM4EALDH1A1HTR6MAPT | |
| SCHEMBL8697270 | 0.81 | POLB (0.49) | POLBKDM4EALDH1A1HTR6MAPT | |
| SCHEMBL8694188 | 0.81 | POLB (0.49) | POLBKDM4EALDH1A1HTR6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109200034-A | A kind of composition and preparation method thereof of inhalable dry powder form | 正大天晴药业集团股份有限公司 | 2019-01-15 | — | — | CN | claimed |
| CN-106749008-A | A kind of method of micronization of maleic acid QAB-149 and its application | 北京九和药业有限公司 | 2017-05-31 | — | — | CN | claimed |
| CN-117083273-A | Crystalline forms of the dihydrochloride salt of a JAK inhibitor compound | 施万生物制药研发IP有限责任公司 | 2023-11-17 | — | — | CN | disclosed |
| CN-114344285-B | Improved inhalable agglomerates | 江苏恒瑞医药股份有限公司 | 2023-11-14 | — | — | CN | disclosed |
| CN-110381951-A | For treating the method and composition of pulmonary hypertension He other lung disorders | 瑞必治公司 | 2019-10-25 | — | — | CN | disclosed |
| CN-110290781-A | The dosage form of stomach and intestine privileged site control release | 南京三迭纪医药科技有限公司 | 2019-09-27 | — | — | CN | disclosed |
| CN-110013481-A | Maleic acid datro application in preparation of anti-tumor drugs | 暨南大学 | 2019-07-16 | — | — | CN | disclosed |
| CN-105188757-B | The inhalable aggregate of porous carrier particle and micronized medication | 诺华股份有限公司 | 2019-04-30 | — | — | CN | disclosed |
| CN-105209013-B | Spray dried formulations are decrystallized through taking off for mixing by spraying | 诺华股份有限公司 | 2019-04-26 | — | — | CN | disclosed |
| CN-104736144-B | Efflux inhibitor compositions and methods of treatment using such compositions | 艾祖米科技有限公司 | 2019-02-01 | — | — | CN | disclosed |
| CN-109200034-A | A kind of composition and preparation method thereof of inhalable dry powder form | 正大天晴药业集团股份有限公司 | 2019-01-15 | — | — | CN | disclosed |
| EP-2066325-A2 | PHARMACEUTICAL COMPOSITIONS OF ARIPIPRAZOLE | Zysis Limited (GB) | 2009-06-10 | — | — | EP | disclosed |
| CN-101296701-A | A combination of compounds, which can be used in the treatment of respiratory diseases, especially chronic obstructive pulmonary disease (COPD) and asthma | ASTRAZENECA AB (SE) | 2008-10-29 | — | — | CN | disclosed |
| CN-101296698-A | Combination of compounds for the treatment of respiratory diseases, in particular Chronic Obstructive Pulmonary Disease (COPD) and asthma | ASTRAZENECA AB (SE) | 2008-10-29 | — | — | CN | disclosed |
| WO-2008125843-A1 | PHARMACEUTICAL COMPOSITIONS | ZYSIS LIMITED (GB) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008038003-A2 | PHARMACEUTICAL COMPOSITIONS OF ARIPIPRAZOLE | ZYSIS LIMITED (GB) | 2008-04-03 | — | — | WO | disclosed |
| EP-1568361-A2 | Sustained-release pharmaceutical composition containing tamsulosin | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2005-08-31 | — | — | EP | disclosed |
| US-20050100602-A1 | Sustained release pharmaceutical composition | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| US-20050100603-A1 | Sustained release pharmaceutical composition | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1529526-A1 | Sustained-release pharmaceutical compositon | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2005-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050100602-A1 | Sustained release pharmaceutical composition | ADRA2A, ADRA2C, ADRA1A | POLB 4781/4885KDM4E 4416/4885ALDH1A1 2853/4885 |
| US-20050100603-A1 | Sustained release pharmaceutical composition | ADRB1, ADRA1B, ADRB2 | POLB 4779/4885KDM4E 4671/4885ALDH1A1 2470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.